{"gene":"TNFRSF14","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"HVEM (TNFRSF14) directly binds HSV glycoprotein D (gD) in a specific physical interaction demonstrated by biosensor and gel filtration chromatography, forming a 1:1 molar ratio complex with apparent mass of ~113 kDa; this interaction mediates HSV entry into HVEM-expressing cells and is dependent on native gD conformation but not N-linked glycosylation.","method":"Biosensor binding assay, gel filtration chromatography, CHO cell infection assay with recombinant HVEM and gD proteins","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified proteins, multiple binding assays, functional entry validation, replicated across multiple labs","pmids":["9223502"],"is_preprint":false},{"year":1997,"finding":"HVEM (ATAR) signals through TRAF2 and TRAF5 via a C-terminal 20-amino-acid intracellular domain, and overexpression of HVEM activates NF-κB; co-expression with TRAF5 (but not TRAF2) produces synergistic NF-κB activation, indicating distinct roles for these two TRAFs downstream of HVEM.","method":"Co-immunoprecipitation, NF-κB reporter assay, overexpression in cell lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional NF-κB readout, single lab, two orthogonal methods","pmids":["9153189"],"is_preprint":false},{"year":1998,"finding":"LIGHT (TNFSF14) is a ligand for HVEM (TR2/HVEM) and induces apoptosis in tumor cells expressing both LTβR and HVEM; HVEM-Fc fusion protein specifically blocks LIGHT cytotoxicity, demonstrating direct LIGHT-HVEM interaction in cell death signaling.","method":"Receptor-Fc fusion protein competition assay, apoptosis assay in tumor cell lines","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional blocking with Fc fusion protein, single lab, consistent with receptor-ligand interaction","pmids":["9739048"],"is_preprint":false},{"year":1998,"finding":"HVEM-L (later identified as LIGHT) binds HVEM-Fc fusion protein with ~44 nM affinity and stimulates T cell proliferation and NF-κB-dependent transcription through HVEM, as shown by binding specificity assays with soluble and membrane forms.","method":"HVEM-Fc fusion protein binding screen, NF-κB reporter assay, T cell proliferation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity measurement with Fc fusion protein, functional NF-κB and proliferation readouts, single lab","pmids":["9765287"],"is_preprint":false},{"year":1998,"finding":"HveA (HVEM) mediates HSV-1-induced cell-cell fusion as well as free virus entry; antibodies against gD and HveA block syncytium formation, and the form of virally expressed gD determines whether HveA can mediate fusion, linking gD-HveA interaction to both entry and fusion.","method":"CHO-HveA cell transfection, syncytium assay, antibody blocking","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay with receptor-expressing cells, antibody blocking, single lab","pmids":["9621040"],"is_preprint":false},{"year":2001,"finding":"X-ray crystal structure of HSV-1 gD ectodomain bound to HveA (HVEM) ectodomain reveals that the gD N-terminal hairpin contacts CRD1 of HVEM, forming a specific binding interface; two anions suggest possible binding sites for 3-O-sulfonated heparan sulfate receptor.","method":"X-ray crystallography of gD alone and gD–HveA complex","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure of receptor-ligand complex, independently validated by multiple subsequent mutagenesis studies","pmids":["11511370"],"is_preprint":false},{"year":2001,"finding":"The gD-binding domain of HveA resides within CRD1 and CRD2 (residues 1–120); CRD1 alone (HveA(76t)) is insufficient for gD binding, and the monoclonal antibody CW3, which blocks a discontinuous epitope in CRD1, inhibits gD binding and virus entry.","method":"Biosensor assay, ELISA, virus entry blocking assay with truncated HveA proteins and monoclonal antibodies","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding with defined protein fragments, antibody-based functional blocking, multiple orthogonal methods in single lab","pmids":["11119586"],"is_preprint":false},{"year":2000,"finding":"gD, LIGHT, and LT-α each bind to distinct sites on HveA (HVEM), as shown by peptide competition assays differentially blocking each ligand; binding of one ligand can alter the conformation of HveA, potentially affecting interaction with other ligands.","method":"Competition binding assay with peptide ligands, soluble receptor forms, and monoclonal antibodies","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple competitive binding assays showing distinct binding sites, single lab","pmids":["11164894"],"is_preprint":false},{"year":2002,"finding":"Structure-based alanine-scanning mutagenesis of HveA identifies a binding hot spot centered on HveA-Y23, which protrudes into a crevice on gD; an intermolecular β-sheet between gD and HveA residues 35–37 contributes to binding, and the C37–C19 disulfide bond in CRD1 is critical for gD binding. CRD2 provides structural support rather than direct contact energy.","method":"Site-directed mutagenesis, biosensor binding assay, virus entry assay, oligomerization analysis","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-guided mutagenesis with functional entry readout, multiple methods, consistent with crystal structure","pmids":["12368332"],"is_preprint":false},{"year":2003,"finding":"Structure-based mutagenesis of gD defines three critical regions at the gD-HveA interface: (i) residues forming an intermolecular β-sheet with HveA are crucial for binding and entry; (ii) residues contacting HveA-Y23 contribute to binding but not entry; (iii) one gD residue contacts CRD2 and contributes to binding.","method":"Site-directed mutagenesis, receptor-binding assay, virus entry assay, cell-cell fusion assay","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-guided mutagenesis with multiple functional readouts, consistent with complementary HveA mutagenesis study","pmids":["12829851"],"is_preprint":false},{"year":2005,"finding":"2.8-Å crystal structure of the BTLA–HVEM complex shows BTLA binds the N-terminal CRD1 of HVEM using a surface that overlaps with the gD binding site and employs a similar binding motif. BTLA is monomeric and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM defines critical binding residues.","method":"X-ray crystallography, light scattering, alanine-scanning mutagenesis of HVEM","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure with mutagenesis validation and stoichiometry measurement","pmids":["16169851"],"is_preprint":false},{"year":2008,"finding":"HVEM-dependent NF-κB activation by HSV-1 gD is mediated through the gD–HVEM interaction: UV-inactivated HSV-1 or soluble gD activates NF-κB only in HVEM-expressing cells; antibodies blocking gD–HVEM binding reduce NF-κB activation; a gD mutant unable to bind HVEM fails to activate NF-κB.","method":"NF-κB reporter assay, antibody blocking, HVEM-transfected and HVEM-deficient cell lines, gD binding mutant","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell systems and gD mutant controls, consistent blocking data, single lab","pmids":["18671825"],"is_preprint":false},{"year":2008,"finding":"gD–HVEM interaction mediates NF-κB-dependent protection against Fas- and staurosporine-induced apoptosis; antibodies blocking gD–HVEM binding reduce this anti-apoptotic effect, and a gD mutant that cannot bind HVEM fails to protect cells.","method":"Apoptosis assay (anti-Fas, staurosporine), antibody blocking, gD binding mutant in HVEM-expressing cells","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional anti-apoptosis assay with blocking antibody and loss-of-function gD mutant, single lab","pmids":["18723002"],"is_preprint":false},{"year":2009,"finding":"BTLA and HVEM form a cis-heterodimeric complex on the surface of naive T cells that inhibits HVEM-dependent NF-κB activation; BTLA ectodomain competitively inhibits trans engagement of BTLA and CD160 with HVEM; LIGHT binds the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization; genetic deletion of BTLA or pharmacologic disruption of the cis-complex promotes HVEM activation in trans.","method":"Co-immunoprecipitation, cell surface binding assay, NF-κB reporter assay, BTLA-KO mice, competitive inhibition assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple functional assays, genetic KO validation, multiple orthogonal methods","pmids":["19915044"],"is_preprint":false},{"year":2011,"finding":"HVEM-deficient memory CD4 T cells (Th2 and Th1) fail to persist after recall antigen encounter, displaying reduced PKB/Akt activity; constitutively active Akt rescues survival of HVEM-deficient Th2 memory cells. LIGHT-deficient T cells recapitulate the HVEM-deficient defect, indicating LIGHT-HVEM T cell–T cell interactions are required for memory T cell persistence.","method":"HVEM-KO and LIGHT-KO mouse models, antigen recall assay, Akt phosphorylation assay, constitutively active Akt rescue","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with biochemical rescue (constitutively active Akt), multiple KO models, two orthogonal genetic approaches","pmids":["21402741"],"is_preprint":false},{"year":2012,"finding":"Epithelial HVEM promotes host defense against intestinal Citrobacter rodentium and pulmonary Streptococcus pneumoniae infection by activating NF-κB-inducing kinase–dependent STAT3 signaling in epithelial cells; CD160 expressed by innate-like intraepithelial lymphocytes is the ligand that engages epithelial HVEM for this protective signaling.","method":"Hvem-/- mouse infection model, STAT3 phosphorylation assay, CD160 identification as HVEM ligand, gene expression analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse with mechanistic signaling pathway (NIK–STAT3) and ligand identification (CD160), two infection models","pmids":["22801499"],"is_preprint":false},{"year":2016,"finding":"Loss of HVEM (TNFRSF14) causes cell-autonomous B cell proliferation and GC lymphoma development in vivo; HVEM-deficient lymphoma B cells disrupt inhibitory HVEM–BTLA cell–cell contacts, leading to exacerbated lymphoid stroma activation and increased TFH cell recruitment; administration of solHVEM(P37-V202) binds BTLA and restores tumor suppression in vivo.","method":"HVEM-KO in vivo lymphoma model, B cell proliferation assay, tumor microenvironment analysis, solHVEM ectodomain treatment, BTLA binding assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO lymphoma model with mechanistic rescue by solHVEM protein, multiple readouts","pmids":["27693350"],"is_preprint":false},{"year":2019,"finding":"HVEM on B cells restrains T helper signals delivered to B cells in germinal centers through a cell-extrinsic mechanism: BTLA on T cells signals via the phosphatase SHP1 to reduce TCR signaling and preformed CD40L mobilization to the immunological synapse, diminishing help to HVEM-expressing B cells; T cell BTLA deficiency combined with B cell Bcl-2 overexpression leads to GC B cell outgrowth.","method":"Genetic deletion of HVEM on B cells, BTLA KO T cells, imaging of immunological synapse (CD40L mobilization), mixed bone marrow chimeras, Bcl-2 transgenic mice","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic models isolating cell-intrinsic vs extrinsic functions, immunological synapse imaging, SHP1-mediated TCR signaling readout","pmids":["31204070"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the CD160–HVEM complex at 2.x Å reveals CD160 adopts a unique Ig fold variant and engages HVEM in a 1:1 complex at a binding interface similar to the BTLA–HVEM interface (CRD1 region), establishing the structural basis for CD160–HVEM bidirectional signaling.","method":"X-ray crystallography, light scattering (stoichiometry determination)","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — atomic-resolution crystal structure with solution stoichiometry, single lab","pmids":["31230945"],"is_preprint":false},{"year":2021,"finding":"Crystal structures reveal that LIGHT and BTLA/CD160 bind to distinct surfaces on HVEM; a human HVEM–LIGHT–CD160 ternary complex structure demonstrates simultaneous binding of both partners. Structure-guided HVEM knock-in mutants selectively recognizing either TNF or Ig ligands in mice show that LIGHT-HVEM signaling is selectively required for bacterial clearance in the intestine, while Ig ligand (BTLA/CD160)–HVEM signaling is selectively required for amelioration of liver inflammation.","method":"X-ray crystallography (ternary complex), structure-based mutagenesis, knock-in mouse models, bacterial infection model, liver inflammation model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — ternary crystal structure plus knock-in mouse genetic dissection with two orthogonal in vivo models","pmids":["34709351"],"is_preprint":false},{"year":2018,"finding":"HVEM signaling in LIGHT-mediated ILC3 activation is required for host defense against Yersinia enterocolitica; LIGHT is the ligand inducing HVEM signals in ILC3 that stimulate protective IFN-γ secretion; adoptive transfer of wild-type but not IFN-γ-deficient ILC3 restores protection in ILC-deficient mice.","method":"HVEM-conditional KO (ILC3-specific), adoptive transfer, IFN-γ production assay, bacterial infection model","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with mechanistic (IFN-γ) and adoptive transfer rescue, two genetic approaches","pmids":["30092201"],"is_preprint":false},{"year":2018,"finding":"HVEM expressed in keratinocytes mediates LIGHT-driven keratinocyte hyperplasia and periostin expression; keratinocyte-specific HVEM deletion or antibody blocking of LIGHT-HVEM reduces epidermal thickening, collagen deposition, and periostin in a house dust mite model of atopic dermatitis; LIGHT directly induces keratinocyte proliferation and periostin through HVEM in human epidermal keratinocytes.","method":"Keratinocyte-conditional HVEM KO mice, antibody blockade of LIGHT-HVEM, atopic dermatitis model, human keratinocyte culture with LIGHT stimulation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus antibody blockade with mechanistic readouts in both mouse and human cells","pmids":["29339444"],"is_preprint":false},{"year":2016,"finding":"TNFRSF14 (HVEM) expression on mast cells mediates TNFSF14 (LIGHT)-enhanced IgE-mediated mast cell signaling and mediator production; reconstitution of MC-deficient mice with TNFRSF14-expressing (but not TNFRSF14-deficient) mast cells restores multiple asthma pathology features including airway hyperreactivity, inflammation, and remodeling.","method":"Tnfrsf14-KO mice, mast-cell-deficient mouse reconstitution with TNFRSF14+/+ vs TNFRSF14-/- MCs, antibody neutralization, IgE signaling assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — two types of MC-deficient mouse reconstitution isolating HVEM function on MCs, with functional IgE signaling readout","pmids":["27982078"],"is_preprint":false},{"year":2011,"finding":"HVEM-BTLA pathway controls homeostasis of CD8α- dendritic cell subsets in the spleen; HVEM- or BTLA-deficient DCs show a specific growth advantage in repopulating the spleen in competitive bone marrow chimeras; DC expression of both HVEM and BTLA is required, and LTβR drives DC expansion that is counter-regulated by the HVEM-BTLA inhibitory checkpoint.","method":"HVEM-KO and BTLA-KO mice, competitive bone marrow chimera, flow cytometry of DC subsets, LTβR agonist treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — competitive chimera establishes cell-intrinsic function, multiple KO strains, agonist treatment confirms pathway epistasis","pmids":["18097025"],"is_preprint":false},{"year":2016,"finding":"BTLA expressed on DEC205+CD8+CD11c+ DCs promotes extrathymic Treg induction; HVEM engagement on T cells upregulates CD5, which in turn enables Foxp3 expression by resisting effector-cytokine-mediated suppression of Foxp3; T cells activated in the absence of BTLA-HVEM signaling remain CD5lo and fail to sustain Foxp3.","method":"BTLA-KO DC transfer, HVEM-KO T cells, CD5 expression analysis, Foxp3 reporter, cytokine stimulation assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO of both BTLA and HVEM with mechanistic intermediate (CD5 upregulation), multiple cell types tested","pmids":["27793593"],"is_preprint":false},{"year":2005,"finding":"LIGHT-HVEM interaction enhances bactericidal activity against Listeria monocytogenes and Staphylococcus aureus in monocytes and neutrophils by increasing phagocytosis, IL-8, TNF-α, nitric oxide, and ROS; anti-HVEM monoclonal antibody blocks all these effects, and ROS/NO inhibition abrogates LIGHT-HVEM-driven bactericidal activity.","method":"Anti-HVEM antibody blockade, ROS/NO inhibitors, cytokine ELISA, bactericidal assay","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-blocking antibody with mechanistic downstream inhibitor studies, single lab","pmids":["16275888"],"is_preprint":false},{"year":2011,"finding":"LIGHT (sLIGHT) enhances adipose tissue inflammatory responses (macrophage chemotaxis, cytokine release) through HVEM; neutralizing anti-HVEM antibody or HVEM knockout abolishes sLIGHT-induced inflammatory responses in macrophages, adipocytes, and SVF cells.","method":"Anti-HVEM neutralizing antibody, HVEM-KO cells/mice, chemotaxis assay, cytokine ELISA","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-blocking antibody plus genetic KO confirmation, single lab","pmids":["21236258"],"is_preprint":false},{"year":2013,"finding":"HVEM promotes CD4+ T cell survival during Strongyloides ratti infection through BTLA engagement; HVEM or BTLA deficiency reduces parasite burden via accelerated mast cell degranulation and increased IL-9 production, placing HVEM upstream of BTLA-mediated suppression of the anti-helminth response.","method":"HVEM-KO and BTLA-KO mice, parasite infection model, mast cell degranulation assay, IL-9 measurement","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — parallel genetic KO of both receptor and ligand, functional immune readouts, single lab","pmids":["25595777"],"is_preprint":false},{"year":2013,"finding":"BTLA expressed on CD8α+ dendritic cells acts as a trans-activating ligand that delivers positive co-signals through HVEM on T cells to promote CD8 T cell memory formation after vaccinia virus infection; mixed adoptive transfer experiments established the trans (DC-to-T cell) direction of this signaling.","method":"HVEM-KO and BTLA-KO mice, vaccinia virus infection, mixed adoptive transfer, memory CD8 T cell quantification","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mixed adoptive transfer establishing cell-type directionality, parallel KO strains, single lab","pmids":["24205056"],"is_preprint":false},{"year":2011,"finding":"BTLA expressed on donor T cells serves a dual role in GVHD: (1) as a receptor transmitting inhibitory signals that suppress anti-host T cell responses; and (2) as a ligand that delivers HVEM pro-survival signals to donor T cells, demonstrated using a BTLA mutant lacking the intracellular signaling domain that rescues impaired T cell survival without transmitting inhibitory signals.","method":"Agonistic anti-BTLA antibody, BTLA intracellular domain deletion mutant, GVHD mouse model, donor T cell survival assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BTLA signaling-domain mutant dissects receptor vs ligand functions, single lab","pmids":["21220749"],"is_preprint":false},{"year":2023,"finding":"MIF (Macrophage Migration Inhibitory Factor) directly binds HVEM and activates NF-κB signaling to promote Th17 cell differentiation; anti-HVEM antibody blockade abolishes MIF-induced Th17 differentiation, establishing HVEM as the receptor mediating MIF's effect.","method":"Direct binding assay (MIF–HVEM), anti-HVEM antibody blockade, NF-κB phosphorylation assay, Th17 differentiation assay","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct binding plus functional blockade, single lab, limited methodological detail in abstract","pmids":["37331297"],"is_preprint":false},{"year":2022,"finding":"In cis, BTLA co-expression with HVEM results in dominant BTLA-mediated inhibition rather than HVEM co-stimulation; LIGHT and CD160 (but not BTLA) co-expression with HVEM induces constitutive HVEM signaling; HVEM antibodies can simultaneously act as checkpoint inhibitors and co-stimulation agonists on primary human T cells.","method":"T cell reporter system, primary human T cell stimulation, HVEM ligand co-expression constructs, NF-κB and NFAT reporter readouts","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter systems plus primary T cell validation, single lab, two orthogonal cell systems","pmids":["36081508"],"is_preprint":false},{"year":2024,"finding":"BTLA on effector CAR T cells inhibits antitumor function by recruiting tyrosine phosphatases SHP-1 and SHP-2 upon trans engagement with HVEM on regulatory T cells in the tumor microenvironment; BTLA knockout in CAR T cells improves tumor control and persistence in lymphoma and solid tumor models.","method":"CRISPR BTLA knockout in CAR T cells, SHP-1/SHP-2 recruitment assay, in vivo tumor models (lymphoma, solid tumors), clinical correlation with CAR T response","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with mechanistic phosphatase recruitment, in vivo validation in multiple tumor models, clinical correlation","pmids":["38831106"],"is_preprint":false},{"year":2020,"finding":"HVEM signaling is required for generating ADCC-mediating IgG2 antibodies after HSV vaccination; Hvem-/- mice produce fewer HSV-specific IgG2 antibodies with reduced ADCC titers and impaired FcγR activation; addition of gD protein or anti-HVEM antibodies to in vitro FcγR activation assays inhibits the response, showing gD–HVEM engagement by HSV blocks host ADCC responses.","method":"Hvem-/- mouse vaccination, passive serum transfer, in vitro FcγR activation assay, antibody isotyping","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse combined with in vitro mechanistic FcγR assay and passive transfer, multiple orthogonal methods","pmids":["32817296"],"is_preprint":false},{"year":2022,"finding":"Epithelial HVEM promotes survival of small intestine intraepithelial T cells (IETs) at steady state by inducing epithelial synthesis of basement membrane protein collagen IV, which engages β1 integrins on IETs; intravital microscopy shows HVEM-deficient epithelium reduces IET patrolling movement; β1 integrin–collagen IV interactions are required for IET maintenance and protective responses to Salmonella.","method":"HVEM conditional KO in epithelium, RNA-seq of organoids, β1 integrin-KO T cells, collagen IV measurement, intravital microscopy, Salmonella infection model","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — epithelial-conditional KO with mechanistic intermediate (collagen IV–β1 integrin axis), intravital imaging, in vivo infection model, multiple orthogonal approaches","pmids":["35905286"],"is_preprint":false},{"year":2013,"finding":"HVEM expression is upregulated in neurons during HSV-1 latency by the viral latency-associated transcript (LAT); LAT upregulates HVEM expression in vivo and in vitro in the absence of other viral factors; HSV-1 latency/reactivation is significantly reduced in Hvem-/- mice, indicating HVEM promotes latency establishment and reactivation.","method":"Hvem-/- mouse latency model, LAT expression constructs, in vivo and in vitro HVEM expression measurement, viral latency quantification","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO mouse plus LAT expression manipulation, single lab, two orthogonal approaches","pmids":["24307582"],"is_preprint":false},{"year":2009,"finding":"LIGHT stimulation through HVEM (but not LTβR) induces upregulation of apoptotic genes and CLL cell death, activation of caspases, loss of mitochondrial membrane potential, upregulation of Bax, and TRAIL involvement; HVEM stimulation also induces endogenous TNF-α production which enhances HVEM-mediated cell death. Other HVEM ligands (gD, BTLA) are largely ineffective in this killing pathway.","method":"Anti-HVEM mAb stimulation, LIGHT treatment, caspase activation assay, mitochondrial membrane potential measurement, Bax immunoblot, TNF-α ELISA, receptor-specific blocking","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic apoptosis pathway readouts with receptor-specific ligands and blocking, single lab","pmids":["19701890"],"is_preprint":false},{"year":2013,"finding":"TNFRSF14 deficiency in ovariectomized mice attenuates adipose tissue inflammation by reducing CD11c+ macrophage recruitment and polarization to M1; LIGHT engagement of TNFRSF14 (HVEM) enhances CD11c expression via ROS generation, identifying HVEM as a redox modulator in adipose tissue inflammatory signaling.","method":"Tnfrsf14-KO mouse ovariectomy model, flow cytometry of CD11c+ cells, ROS measurement, bone marrow-derived macrophage polarization assay","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with mechanistic ROS pathway readout, single lab","pmids":["24287621"],"is_preprint":false}],"current_model":"HVEM (TNFRSF14) is a TNF receptor superfamily member that functions as a bidirectional molecular switch: it acts as a signaling receptor for TNF-family ligands LIGHT and LTα (activating NF-κB via TRAF2/TRAF5 and NIK–STAT3 pathways to drive inflammatory and survival responses) and simultaneously as a ligand for Ig-superfamily members BTLA and CD160, which in trans engagement activate HVEM-dependent NF-κB while in cis the HVEM–BTLA heterodimer on naive T cells is inhibitory; structurally, BTLA and CD160 bind CRD1 of HVEM (the same surface used by HSV gD) while LIGHT binds a distinct surface, allowing ternary complex formation; downstream, HVEM promotes memory T cell survival via Akt, drives epithelial STAT3 activation and collagen IV synthesis to maintain intraepithelial T cells, stimulates ILC3-derived IFN-γ for mucosal defense, and restrains germinal center B cell expansion by limiting TFH help through the BTLA–SHP1 axis, while its frequent somatic mutation or loss in germinal center lymphomas disrupts HVEM–BTLA tumor-suppressive interactions."},"narrative":{"mechanistic_narrative":"TNFRSF14 (HVEM) is a TNF receptor superfamily member that operates as a bidirectional molecular switch coordinating immune signaling, mucosal defense, and tissue homeostasis [PMID:21402741, PMID:22801499, PMID:34709351]. As a signaling receptor, HVEM engages the TNF-family ligand LIGHT (TNFSF14) to activate NF-κB through a C-terminal intracellular domain that recruits TRAF2 and TRAF5, driving T cell proliferation, survival, and inflammatory responses [PMID:9153189, PMID:9765287]. HVEM also functions in reverse as a ligand for the Ig-superfamily receptors BTLA and CD160: in trans these engagements activate HVEM-dependent NF-κB, whereas in cis the BTLA–HVEM heterodimer on naive T cells dominantly inhibits HVEM oligomerization and signaling [PMID:19915044, PMID:36081508]. Structurally, BTLA and CD160 bind the N-terminal CRD1 of HVEM—the same surface used by HSV glycoprotein D—while LIGHT occupies a distinct surface, permitting assembly of a LIGHT–HVEM–CD160 ternary complex and genetically separable TNF-ligand versus Ig-ligand functions [PMID:16169851, PMID:31230945, PMID:34709351]. Through these inputs HVEM supports memory T cell persistence via Akt [PMID:21402741], drives epithelial NIK–STAT3 signaling and collagen IV synthesis to sustain intraepithelial T cells and antibacterial defense [PMID:22801499, PMID:35905286], stimulates ILC3-derived IFN-γ [PMID:30092201], and restrains germinal center B cell expansion through the BTLA–SHP1 axis [PMID:31204070]. The inhibitory BTLA arm engages SHP-1/SHP-2 phosphatases, and its loss in HVEM-deficient B cells produces cell-autonomous germinal center lymphoma that is suppressed by soluble HVEM ectodomain binding BTLA [PMID:27693350, PMID:38831106]. HVEM is additionally exploited by HSV: gD binding via CRD1 mediates viral entry and cell-cell fusion and blocks host ADCC responses [PMID:9223502, PMID:9621040, PMID:32817296].","teleology":[{"year":1997,"claim":"Establishing HVEM's first identified function answered how HSV-1 enters cells, defining HVEM as a direct viral entry receptor.","evidence":"Biosensor binding and gel filtration with purified gD and HVEM plus CHO cell infection assays","pmids":["9223502"],"confidence":"High","gaps":["Did not define the HVEM residues contacting gD","Cellular signaling consequences of gD binding not addressed"]},{"year":1997,"claim":"Identifying TRAF2/TRAF5 recruitment and NF-κB activation answered how the HVEM cytoplasmic tail transduces signals.","evidence":"Co-immunoprecipitation and NF-κB reporter assays with HVEM overexpression","pmids":["9153189"],"confidence":"Medium","gaps":["Distinct roles of TRAF2 vs TRAF5 only inferred from synergy","No physiological ligand context in this study"]},{"year":1998,"claim":"Identifying LIGHT as a physiological HVEM ligand answered what TNF-family input drives HVEM signaling versus apoptosis.","evidence":"HVEM-Fc fusion competition, affinity measurement, NF-κB reporter, T cell proliferation and tumor apoptosis assays","pmids":["9739048","9765287"],"confidence":"Medium","gaps":["Apoptotic versus proliferative outcome dependence on receptor co-expression (LTβR) not fully resolved","Single-lab affinity measurements"]},{"year":2001,"claim":"Crystal structures and truncation mapping answered where gD binds HVEM, localizing the interface to CRD1/CRD2.","evidence":"X-ray crystallography of gD–HveA complex and biosensor/ELISA with truncated HveA and blocking antibodies","pmids":["11511370","11119586"],"confidence":"High","gaps":["Energetic contribution of individual residues not yet defined","Relationship to other ligand sites not addressed structurally"]},{"year":2000,"claim":"Competition mapping answered whether HVEM ligands share or use distinct surfaces, revealing gD, LIGHT, and LTα occupy separable sites with conformational coupling.","evidence":"Peptide and soluble receptor competition binding assays with monoclonal antibodies","pmids":["11164894"],"confidence":"Medium","gaps":["Atomic basis of conformational coupling not defined","Ig-superfamily ligands not yet included"]},{"year":2002,"claim":"Structure-guided mutagenesis of both partners pinpointed the gD–HVEM binding hot spot (HveA-Y23, intermolecular β-sheet, CRD1 disulfide), distinguishing binding from entry determinants.","evidence":"Alanine-scanning and site-directed mutagenesis with biosensor binding and virus entry/fusion assays","pmids":["12368332","12829851"],"confidence":"High","gaps":["Did not address how these residues influence cellular signaling","Generalization to immune ligands not tested"]},{"year":2005,"claim":"The BTLA–HVEM crystal structure answered how an Ig-superfamily receptor engages HVEM, showing CRD1 binding overlapping the gD site.","evidence":"X-ray crystallography, light scattering stoichiometry, alanine-scanning mutagenesis of HVEM","pmids":["16169851"],"confidence":"High","gaps":["Functional consequence of overlap with gD site not tested here","Cis versus trans engagement not addressed"]},{"year":2008,"claim":"Functional studies answered whether gD–HVEM engagement itself signals, showing it activates NF-κB and confers anti-apoptotic protection.","evidence":"NF-κB reporter and apoptosis assays with HVEM-deficient/transfected cells, blocking antibodies, and a gD binding mutant","pmids":["18671825","18723002"],"confidence":"Medium","gaps":["Downstream effectors of anti-apoptotic signaling not fully mapped","Single-lab findings"]},{"year":2009,"claim":"Discovery of the cis BTLA–HVEM heterodimer answered how naive T cells set their signaling baseline, defining a dominant inhibitory configuration.","evidence":"Reciprocal Co-IP, surface binding, NF-κB reporter, and BTLA-KO mice with competitive inhibition assays","pmids":["19915044"],"confidence":"High","gaps":["Precise mechanism by which cis BTLA blocks HVEM oligomerization not structurally resolved"]},{"year":2011,"claim":"Genetic models answered how HVEM contributes to adaptive immunity, linking LIGHT–HVEM signaling to memory T cell survival via Akt and to dendritic cell homeostasis via the BTLA checkpoint.","evidence":"HVEM-KO and LIGHT-KO mice with antigen recall, Akt phosphorylation and constitutively active Akt rescue, and competitive bone marrow chimeras","pmids":["21402741","18097025"],"confidence":"High","gaps":["Molecular link between HVEM and Akt activation not defined","Cell-cell directionality (T-T vs DC) requires distinct models"]},{"year":2012,"claim":"Epithelial studies answered how HVEM contributes to mucosal defense, defining a CD160–HVEM–NIK–STAT3 axis protecting against bacterial infection.","evidence":"Hvem-/- mouse infection models with STAT3 phosphorylation and CD160 ligand identification","pmids":["22801499"],"confidence":"High","gaps":["Relative contribution of CD160 vs LIGHT in different tissues not yet dissected"]},{"year":2016,"claim":"Tumor and Treg studies answered how loss of HVEM–BTLA interactions promotes malignancy and how the pathway shapes tolerance, establishing HVEM as a B cell tumor suppressor and a CD5/Foxp3-promoting signal.","evidence":"HVEM-KO in vivo lymphoma model with solHVEM ectodomain rescue, and BTLA/HVEM-KO models tracking CD5 and Foxp3","pmids":["27693350","27793593"],"confidence":"High","gaps":["Whether solHVEM therapy translates beyond the mouse model not addressed","Signaling linking HVEM engagement to CD5 upregulation not fully defined"]},{"year":2019,"claim":"Mechanistic and structural studies answered how the inhibitory arm restrains germinal centers and how CD160 engages HVEM, defining a BTLA–SHP1 cell-extrinsic brake and a CRD1-based CD160 interface.","evidence":"Conditional HVEM/BTLA deletion with immunological synapse imaging and SHP1 readout, plus X-ray crystallography of the CD160–HVEM complex","pmids":["31204070","31230945"],"confidence":"High","gaps":["Quantitative integration of cis and trans signaling in vivo not resolved"]},{"year":2021,"claim":"The ternary complex structure plus ligand-selective knock-in mice answered whether TNF and Ig ligand arms are genetically separable, showing LIGHT-HVEM and BTLA/CD160-HVEM control distinct tissue functions.","evidence":"X-ray crystallography of LIGHT–HVEM–CD160 ternary complex with structure-based knock-in mice and infection/inflammation models","pmids":["34709351"],"confidence":"High","gaps":["How simultaneous ligand binding modulates signaling output quantitatively not defined"]},{"year":2024,"claim":"Mechanistic dissection in CAR T cells answered how trans BTLA–HVEM engagement constrains effector function, identifying SHP-1/SHP-2 recruitment as the inhibitory output and a therapeutic target.","evidence":"CRISPR BTLA knockout in CAR T cells with phosphatase recruitment assays and in vivo tumor models","pmids":["38831106"],"confidence":"High","gaps":["Whether HVEM-side signaling contributes to this axis in tumors not addressed"]},{"year":null,"claim":"How the balance between cis-inhibitory and trans-activating HVEM configurations is dynamically regulated across cell types and disease states, and how this could be therapeutically tuned, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the cis BTLA–HVEM heterodimer","Mechanism switching cells between cis and trans engagement undefined","Stoichiometry of signaling-competent HVEM clusters in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[13,16,17]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,3,15,19]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,31]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,13,15,34]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,15,17,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,16,35]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,36]}],"complexes":["HVEM–BTLA cis-heterodimer","LIGHT–HVEM–CD160 ternary complex"],"partners":["LIGHT","BTLA","CD160","TRAF2","TRAF5","LTA","MIF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92956","full_name":"Tumor necrosis factor receptor superfamily member 14","aliases":["Herpes virus entry mediator A","Herpesvirus entry mediator A","HveA","Tumor necrosis factor receptor-like 2","TR2"],"length_aa":283,"mass_kda":30.4,"function":"Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network (PubMed:10754304, PubMed:18193050, PubMed:23761635, PubMed:9462508). Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation (PubMed:19915044, PubMed:9153189, PubMed:9162022). Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions (PubMed:10754304). Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response (PubMed:23761635). In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity). Upon binding to CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with BTLA (By similarity) (PubMed:19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (By similarity) (PubMed:19915044) (Microbial infection) Acts as a receptor for Herpes simplex virus 1/HHV-1 (Microbial infection) Acts as a receptor for Herpes simplex virus 2/HHV-2","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q92956/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF14","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF14","total_profiled":1310},"omim":[{"mim_id":"607925","title":"B- AND T-LYMPHOCYTE ATTENUATOR; BTLA","url":"https://www.omim.org/entry/607925"},{"mim_id":"605341","title":"PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, ALPHA; PILRA","url":"https://www.omim.org/entry/605341"},{"mim_id":"605027","title":"LYMPHOMA, NON-HODGKIN, FAMILIAL","url":"https://www.omim.org/entry/605027"},{"mim_id":"604520","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 14; TNFSF14","url":"https://www.omim.org/entry/604520"},{"mim_id":"602746","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14","url":"https://www.omim.org/entry/602746"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF14"},"hgnc":{"alias_symbol":["HVEM","ATAR","TR2","LIGHTR","HVEA","CD270"],"prev_symbol":[]},"alphafold":{"accession":"Q92956","domains":[{"cath_id":"2.10.50.10","chopping":"39-95","consensus_level":"medium","plddt":95.7056,"start":39,"end":95},{"cath_id":"-","chopping":"147-179","consensus_level":"medium","plddt":95.3718,"start":147,"end":179}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92956","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92956-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92956-F1-predicted_aligned_error_v6.png","plddt_mean":79.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF14","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF14"},"sequence":{"accession":"Q92956","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92956.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92956/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92956"}},"corpus_meta":[{"pmid":"11511370","id":"PMC_11511370","title":"Herpes simplex virus glycoprotein D bound to the human receptor HveA.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11511370","citation_count":319,"is_preprint":false},{"pmid":"16932752","id":"PMC_16932752","title":"Balancing co-stimulation and inhibition with BTLA and HVEM.","date":"2006","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16932752","citation_count":258,"is_preprint":false},{"pmid":"9223502","id":"PMC_9223502","title":"Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9223502","citation_count":255,"is_preprint":false},{"pmid":"19426226","id":"PMC_19426226","title":"The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426226","citation_count":247,"is_preprint":false},{"pmid":"9739048","id":"PMC_9739048","title":"LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9739048","citation_count":211,"is_preprint":false},{"pmid":"27693350","id":"PMC_27693350","title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27693350","citation_count":207,"is_preprint":false},{"pmid":"22017438","id":"PMC_22017438","title":"The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017438","citation_count":199,"is_preprint":false},{"pmid":"9765287","id":"PMC_9765287","title":"Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9765287","citation_count":193,"is_preprint":false},{"pmid":"20307212","id":"PMC_20307212","title":"Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.","date":"2010","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20307212","citation_count":188,"is_preprint":false},{"pmid":"9153189","id":"PMC_9153189","title":"ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9153189","citation_count":148,"is_preprint":false},{"pmid":"16169851","id":"PMC_16169851","title":"Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169851","citation_count":140,"is_preprint":false},{"pmid":"20007250","id":"PMC_20007250","title":"HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20007250","citation_count":133,"is_preprint":false},{"pmid":"19915044","id":"PMC_19915044","title":"T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19915044","citation_count":132,"is_preprint":false},{"pmid":"27793593","id":"PMC_27793593","title":"Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27793593","citation_count":122,"is_preprint":false},{"pmid":"22801499","id":"PMC_22801499","title":"HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22801499","citation_count":119,"is_preprint":false},{"pmid":"18519647","id":"PMC_18519647","title":"A crucial role for HVEM and BTLA in preventing intestinal inflammation.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18519647","citation_count":116,"is_preprint":false},{"pmid":"12787566","id":"PMC_12787566","title":"LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787566","citation_count":109,"is_preprint":false},{"pmid":"27257180","id":"PMC_27257180","title":"Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27257180","citation_count":105,"is_preprint":false},{"pmid":"12829851","id":"PMC_12829851","title":"Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12829851","citation_count":103,"is_preprint":false},{"pmid":"12915538","id":"PMC_12915538","title":"Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12915538","citation_count":98,"is_preprint":false},{"pmid":"21106644","id":"PMC_21106644","title":"Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/21106644","citation_count":93,"is_preprint":false},{"pmid":"12368332","id":"PMC_12368332","title":"Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12368332","citation_count":90,"is_preprint":false},{"pmid":"31204070","id":"PMC_31204070","title":"The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31204070","citation_count":90,"is_preprint":false},{"pmid":"11901205","id":"PMC_11901205","title":"Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11901205","citation_count":90,"is_preprint":false},{"pmid":"18097025","id":"PMC_18097025","title":"The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18097025","citation_count":77,"is_preprint":false},{"pmid":"37649037","id":"PMC_37649037","title":"Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37649037","citation_count":71,"is_preprint":false},{"pmid":"9621040","id":"PMC_9621040","title":"HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9621040","citation_count":71,"is_preprint":false},{"pmid":"30984188","id":"PMC_30984188","title":"BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30984188","citation_count":70,"is_preprint":false},{"pmid":"18502984","id":"PMC_18502984","title":"HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18502984","citation_count":67,"is_preprint":false},{"pmid":"21402741","id":"PMC_21402741","title":"Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21402741","citation_count":62,"is_preprint":false},{"pmid":"23439006","id":"PMC_23439006","title":"Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23439006","citation_count":60,"is_preprint":false},{"pmid":"22445654","id":"PMC_22445654","title":"The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.","date":"2012","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22445654","citation_count":59,"is_preprint":false},{"pmid":"16275888","id":"PMC_16275888","title":"LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16275888","citation_count":58,"is_preprint":false},{"pmid":"17179227","id":"PMC_17179227","title":"Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17179227","citation_count":58,"is_preprint":false},{"pmid":"15922943","id":"PMC_15922943","title":"The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15922943","citation_count":56,"is_preprint":false},{"pmid":"34532285","id":"PMC_34532285","title":"BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34532285","citation_count":55,"is_preprint":false},{"pmid":"26965583","id":"PMC_26965583","title":"Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.","date":"2016","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/26965583","citation_count":54,"is_preprint":false},{"pmid":"23445872","id":"PMC_23445872","title":"Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.","date":"2013","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/23445872","citation_count":53,"is_preprint":false},{"pmid":"24205056","id":"PMC_24205056","title":"CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24205056","citation_count":50,"is_preprint":false},{"pmid":"30092201","id":"PMC_30092201","title":"LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection.","date":"2018","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/30092201","citation_count":49,"is_preprint":false},{"pmid":"11119586","id":"PMC_11119586","title":"Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11119586","citation_count":47,"is_preprint":false},{"pmid":"19760072","id":"PMC_19760072","title":"Targeting the LIGHT-HVEM pathway.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760072","citation_count":45,"is_preprint":false},{"pmid":"15917993","id":"PMC_15917993","title":"Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.","date":"2005","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/15917993","citation_count":45,"is_preprint":false},{"pmid":"30885361","id":"PMC_30885361","title":"HVEM network signaling in cancer.","date":"2019","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30885361","citation_count":44,"is_preprint":false},{"pmid":"24307582","id":"PMC_24307582","title":"Interactions between herpesvirus entry mediator (TNFRSF14) and latency-associated transcript during herpes simplex virus 1 latency.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24307582","citation_count":44,"is_preprint":false},{"pmid":"21220749","id":"PMC_21220749","title":"Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21220749","citation_count":44,"is_preprint":false},{"pmid":"8241550","id":"PMC_8241550","title":"HVEM ultrastructural analysis of mouse fungiform taste buds, cell types, and associated synapses.","date":"1993","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/8241550","citation_count":44,"is_preprint":false},{"pmid":"18671825","id":"PMC_18671825","title":"Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D.","date":"2008","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18671825","citation_count":43,"is_preprint":false},{"pmid":"30718814","id":"PMC_30718814","title":"Mechanism of regulation and neutralization of the AtaR-AtaT toxin-antitoxin system.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30718814","citation_count":42,"is_preprint":false},{"pmid":"17145304","id":"PMC_17145304","title":"BTLA and HVEM cross talk regulates inhibition and costimulation.","date":"2006","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17145304","citation_count":40,"is_preprint":false},{"pmid":"30429008","id":"PMC_30429008","title":"The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.","date":"2018","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/30429008","citation_count":40,"is_preprint":false},{"pmid":"18723002","id":"PMC_18723002","title":"Involvement of gD/HVEM interaction in NF-kB-dependent inhibition of apoptosis by HSV-1 gD.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18723002","citation_count":40,"is_preprint":false},{"pmid":"33917094","id":"PMC_33917094","title":"BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33917094","citation_count":39,"is_preprint":false},{"pmid":"38831106","id":"PMC_38831106","title":"The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38831106","citation_count":38,"is_preprint":false},{"pmid":"29339444","id":"PMC_29339444","title":"LIGHT-HVEM signaling in keratinocytes controls development of dermatitis.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29339444","citation_count":38,"is_preprint":false},{"pmid":"30116751","id":"PMC_30116751","title":"Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30116751","citation_count":38,"is_preprint":false},{"pmid":"28612127","id":"PMC_28612127","title":"Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.","date":"2017","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28612127","citation_count":37,"is_preprint":false},{"pmid":"11164894","id":"PMC_11164894","title":"The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11164894","citation_count":36,"is_preprint":false},{"pmid":"36081508","id":"PMC_36081508","title":"BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36081508","citation_count":36,"is_preprint":false},{"pmid":"31230945","id":"PMC_31230945","title":"Structural Basis of CD160:HVEM Recognition.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31230945","citation_count":35,"is_preprint":false},{"pmid":"14562115","id":"PMC_14562115","title":"Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14562115","citation_count":35,"is_preprint":false},{"pmid":"21236258","id":"PMC_21236258","title":"LIGHT/TNFSF14 enhances adipose tissue inflammatory responses through its interaction with HVEM.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21236258","citation_count":35,"is_preprint":false},{"pmid":"27982078","id":"PMC_27982078","title":"A TNFRSF14-FcɛRI-mast cell pathway contributes to development of multiple features of asthma pathology in mice.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27982078","citation_count":34,"is_preprint":false},{"pmid":"19495760","id":"PMC_19495760","title":"Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners.","date":"2009","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19495760","citation_count":33,"is_preprint":false},{"pmid":"19701890","id":"PMC_19701890","title":"A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19701890","citation_count":33,"is_preprint":false},{"pmid":"25595777","id":"PMC_25595777","title":"Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25595777","citation_count":33,"is_preprint":false},{"pmid":"22993162","id":"PMC_22993162","title":"A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22993162","citation_count":33,"is_preprint":false},{"pmid":"19129446","id":"PMC_19129446","title":"Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition.","date":"2009","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19129446","citation_count":32,"is_preprint":false},{"pmid":"22297640","id":"PMC_22297640","title":"Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22297640","citation_count":30,"is_preprint":false},{"pmid":"27103745","id":"PMC_27103745","title":"TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27103745","citation_count":29,"is_preprint":false},{"pmid":"11976496","id":"PMC_11976496","title":"Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA.","date":"2002","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/11976496","citation_count":28,"is_preprint":false},{"pmid":"22345445","id":"PMC_22345445","title":"Herpes B virus utilizes human nectin-1 but not HVEM or PILRα for cell-cell fusion and virus entry.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22345445","citation_count":28,"is_preprint":false},{"pmid":"28594868","id":"PMC_28594868","title":"Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28594868","citation_count":28,"is_preprint":false},{"pmid":"2424939","id":"PMC_2424939","title":"The synaptic ultrastructure in the outer plexiform layer of the catfish retina: a three-dimensional study with HVEM and conventional EM of Golgi-impregnated bipolar and horizontal cells.","date":"1986","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/2424939","citation_count":28,"is_preprint":false},{"pmid":"35905286","id":"PMC_35905286","title":"Epithelial HVEM maintains intraepithelial T cell survival and contributes to host protection.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35905286","citation_count":27,"is_preprint":false},{"pmid":"34208480","id":"PMC_34208480","title":"Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34208480","citation_count":27,"is_preprint":false},{"pmid":"19234349","id":"PMC_19234349","title":"Role of nectin-1, HVEM, and PILR-alpha in HSV-2 entry into human retinal pigment epithelial cells.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19234349","citation_count":27,"is_preprint":false},{"pmid":"17893608","id":"PMC_17893608","title":"Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance.","date":"2007","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/17893608","citation_count":27,"is_preprint":false},{"pmid":"23333859","id":"PMC_23333859","title":"HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.","date":"2013","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/23333859","citation_count":26,"is_preprint":false},{"pmid":"24851095","id":"PMC_24851095","title":"HVEM is a TNF Receptor with Multiple Regulatory Roles in the Mucosal Immune System.","date":"2014","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/24851095","citation_count":26,"is_preprint":false},{"pmid":"28701403","id":"PMC_28701403","title":"Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28701403","citation_count":26,"is_preprint":false},{"pmid":"34709351","id":"PMC_34709351","title":"HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34709351","citation_count":25,"is_preprint":false},{"pmid":"23356438","id":"PMC_23356438","title":"LIGHT/HVEM/LTβR interaction as a target for the modulation of the allogeneic immune response in transplantation.","date":"2013","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/23356438","citation_count":25,"is_preprint":false},{"pmid":"34478526","id":"PMC_34478526","title":"Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34478526","citation_count":25,"is_preprint":false},{"pmid":"15925518","id":"PMC_15925518","title":"Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling.","date":"2005","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/15925518","citation_count":25,"is_preprint":false},{"pmid":"18840367","id":"PMC_18840367","title":"An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.","date":"2008","source":"Clinical therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18840367","citation_count":25,"is_preprint":false},{"pmid":"9445042","id":"PMC_9445042","title":"Herpesvirus entry mediator HVEM mediates cell-cell spread in BHK(TK-) cell clones.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9445042","citation_count":24,"is_preprint":false},{"pmid":"27458100","id":"PMC_27458100","title":"Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.","date":"2016","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/27458100","citation_count":24,"is_preprint":false},{"pmid":"38387336","id":"PMC_38387336","title":"The BTLA-HVEM complex - The future of cancer immunotherapy.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38387336","citation_count":23,"is_preprint":false},{"pmid":"31963646","id":"PMC_31963646","title":"Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31963646","citation_count":23,"is_preprint":false},{"pmid":"26650888","id":"PMC_26650888","title":"Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26650888","citation_count":23,"is_preprint":false},{"pmid":"29858685","id":"PMC_29858685","title":"Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.","date":"2018","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29858685","citation_count":23,"is_preprint":false},{"pmid":"10366573","id":"PMC_10366573","title":"Functional characterization of the HveA homolog specified by African green monkey kidney cells with a herpes simplex virus expressing the green fluorescence protein.","date":"1999","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/10366573","citation_count":23,"is_preprint":false},{"pmid":"32817296","id":"PMC_32817296","title":"HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32817296","citation_count":22,"is_preprint":false},{"pmid":"24287621","id":"PMC_24287621","title":"TNFRSF14 deficiency protects against ovariectomy-induced adipose tissue inflammation.","date":"2013","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24287621","citation_count":21,"is_preprint":false},{"pmid":"37331297","id":"PMC_37331297","title":"MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37331297","citation_count":21,"is_preprint":false},{"pmid":"19895317","id":"PMC_19895317","title":"Expression of herpes virus entry mediator (HVEM) in the cornea and trigeminal ganglia of normal and HSV-1 infected mice.","date":"2009","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19895317","citation_count":21,"is_preprint":false},{"pmid":"28114589","id":"PMC_28114589","title":"Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28114589","citation_count":21,"is_preprint":false},{"pmid":"16675194","id":"PMC_16675194","title":"Prevention of the interaction between HVEM, herpes virus entry mediator, and gD, HSV envelope protein, by a Keggin polyoxotungstate, PM-19.","date":"2006","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16675194","citation_count":21,"is_preprint":false},{"pmid":"23067542","id":"PMC_23067542","title":"The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.","date":"2012","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23067542","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49650,"output_tokens":9236,"usd":0.143745,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19678,"output_tokens":4797,"usd":0.109158,"stage2_stop_reason":"end_turn"},"total_usd":0.252903,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"HVEM (TNFRSF14) directly binds HSV glycoprotein D (gD) in a specific physical interaction demonstrated by biosensor and gel filtration chromatography, forming a 1:1 molar ratio complex with apparent mass of ~113 kDa; this interaction mediates HSV entry into HVEM-expressing cells and is dependent on native gD conformation but not N-linked glycosylation.\",\n      \"method\": \"Biosensor binding assay, gel filtration chromatography, CHO cell infection assay with recombinant HVEM and gD proteins\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified proteins, multiple binding assays, functional entry validation, replicated across multiple labs\",\n      \"pmids\": [\"9223502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HVEM (ATAR) signals through TRAF2 and TRAF5 via a C-terminal 20-amino-acid intracellular domain, and overexpression of HVEM activates NF-κB; co-expression with TRAF5 (but not TRAF2) produces synergistic NF-κB activation, indicating distinct roles for these two TRAFs downstream of HVEM.\",\n      \"method\": \"Co-immunoprecipitation, NF-κB reporter assay, overexpression in cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional NF-κB readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"9153189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"LIGHT (TNFSF14) is a ligand for HVEM (TR2/HVEM) and induces apoptosis in tumor cells expressing both LTβR and HVEM; HVEM-Fc fusion protein specifically blocks LIGHT cytotoxicity, demonstrating direct LIGHT-HVEM interaction in cell death signaling.\",\n      \"method\": \"Receptor-Fc fusion protein competition assay, apoptosis assay in tumor cell lines\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional blocking with Fc fusion protein, single lab, consistent with receptor-ligand interaction\",\n      \"pmids\": [\"9739048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HVEM-L (later identified as LIGHT) binds HVEM-Fc fusion protein with ~44 nM affinity and stimulates T cell proliferation and NF-κB-dependent transcription through HVEM, as shown by binding specificity assays with soluble and membrane forms.\",\n      \"method\": \"HVEM-Fc fusion protein binding screen, NF-κB reporter assay, T cell proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity measurement with Fc fusion protein, functional NF-κB and proliferation readouts, single lab\",\n      \"pmids\": [\"9765287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HveA (HVEM) mediates HSV-1-induced cell-cell fusion as well as free virus entry; antibodies against gD and HveA block syncytium formation, and the form of virally expressed gD determines whether HveA can mediate fusion, linking gD-HveA interaction to both entry and fusion.\",\n      \"method\": \"CHO-HveA cell transfection, syncytium assay, antibody blocking\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay with receptor-expressing cells, antibody blocking, single lab\",\n      \"pmids\": [\"9621040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"X-ray crystal structure of HSV-1 gD ectodomain bound to HveA (HVEM) ectodomain reveals that the gD N-terminal hairpin contacts CRD1 of HVEM, forming a specific binding interface; two anions suggest possible binding sites for 3-O-sulfonated heparan sulfate receptor.\",\n      \"method\": \"X-ray crystallography of gD alone and gD–HveA complex\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure of receptor-ligand complex, independently validated by multiple subsequent mutagenesis studies\",\n      \"pmids\": [\"11511370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The gD-binding domain of HveA resides within CRD1 and CRD2 (residues 1–120); CRD1 alone (HveA(76t)) is insufficient for gD binding, and the monoclonal antibody CW3, which blocks a discontinuous epitope in CRD1, inhibits gD binding and virus entry.\",\n      \"method\": \"Biosensor assay, ELISA, virus entry blocking assay with truncated HveA proteins and monoclonal antibodies\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding with defined protein fragments, antibody-based functional blocking, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"11119586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"gD, LIGHT, and LT-α each bind to distinct sites on HveA (HVEM), as shown by peptide competition assays differentially blocking each ligand; binding of one ligand can alter the conformation of HveA, potentially affecting interaction with other ligands.\",\n      \"method\": \"Competition binding assay with peptide ligands, soluble receptor forms, and monoclonal antibodies\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple competitive binding assays showing distinct binding sites, single lab\",\n      \"pmids\": [\"11164894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Structure-based alanine-scanning mutagenesis of HveA identifies a binding hot spot centered on HveA-Y23, which protrudes into a crevice on gD; an intermolecular β-sheet between gD and HveA residues 35–37 contributes to binding, and the C37–C19 disulfide bond in CRD1 is critical for gD binding. CRD2 provides structural support rather than direct contact energy.\",\n      \"method\": \"Site-directed mutagenesis, biosensor binding assay, virus entry assay, oligomerization analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-guided mutagenesis with functional entry readout, multiple methods, consistent with crystal structure\",\n      \"pmids\": [\"12368332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Structure-based mutagenesis of gD defines three critical regions at the gD-HveA interface: (i) residues forming an intermolecular β-sheet with HveA are crucial for binding and entry; (ii) residues contacting HveA-Y23 contribute to binding but not entry; (iii) one gD residue contacts CRD2 and contributes to binding.\",\n      \"method\": \"Site-directed mutagenesis, receptor-binding assay, virus entry assay, cell-cell fusion assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-guided mutagenesis with multiple functional readouts, consistent with complementary HveA mutagenesis study\",\n      \"pmids\": [\"12829851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"2.8-Å crystal structure of the BTLA–HVEM complex shows BTLA binds the N-terminal CRD1 of HVEM using a surface that overlaps with the gD binding site and employs a similar binding motif. BTLA is monomeric and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM defines critical binding residues.\",\n      \"method\": \"X-ray crystallography, light scattering, alanine-scanning mutagenesis of HVEM\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure with mutagenesis validation and stoichiometry measurement\",\n      \"pmids\": [\"16169851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HVEM-dependent NF-κB activation by HSV-1 gD is mediated through the gD–HVEM interaction: UV-inactivated HSV-1 or soluble gD activates NF-κB only in HVEM-expressing cells; antibodies blocking gD–HVEM binding reduce NF-κB activation; a gD mutant unable to bind HVEM fails to activate NF-κB.\",\n      \"method\": \"NF-κB reporter assay, antibody blocking, HVEM-transfected and HVEM-deficient cell lines, gD binding mutant\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell systems and gD mutant controls, consistent blocking data, single lab\",\n      \"pmids\": [\"18671825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"gD–HVEM interaction mediates NF-κB-dependent protection against Fas- and staurosporine-induced apoptosis; antibodies blocking gD–HVEM binding reduce this anti-apoptotic effect, and a gD mutant that cannot bind HVEM fails to protect cells.\",\n      \"method\": \"Apoptosis assay (anti-Fas, staurosporine), antibody blocking, gD binding mutant in HVEM-expressing cells\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional anti-apoptosis assay with blocking antibody and loss-of-function gD mutant, single lab\",\n      \"pmids\": [\"18723002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BTLA and HVEM form a cis-heterodimeric complex on the surface of naive T cells that inhibits HVEM-dependent NF-κB activation; BTLA ectodomain competitively inhibits trans engagement of BTLA and CD160 with HVEM; LIGHT binds the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization; genetic deletion of BTLA or pharmacologic disruption of the cis-complex promotes HVEM activation in trans.\",\n      \"method\": \"Co-immunoprecipitation, cell surface binding assay, NF-κB reporter assay, BTLA-KO mice, competitive inhibition assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple functional assays, genetic KO validation, multiple orthogonal methods\",\n      \"pmids\": [\"19915044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HVEM-deficient memory CD4 T cells (Th2 and Th1) fail to persist after recall antigen encounter, displaying reduced PKB/Akt activity; constitutively active Akt rescues survival of HVEM-deficient Th2 memory cells. LIGHT-deficient T cells recapitulate the HVEM-deficient defect, indicating LIGHT-HVEM T cell–T cell interactions are required for memory T cell persistence.\",\n      \"method\": \"HVEM-KO and LIGHT-KO mouse models, antigen recall assay, Akt phosphorylation assay, constitutively active Akt rescue\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with biochemical rescue (constitutively active Akt), multiple KO models, two orthogonal genetic approaches\",\n      \"pmids\": [\"21402741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Epithelial HVEM promotes host defense against intestinal Citrobacter rodentium and pulmonary Streptococcus pneumoniae infection by activating NF-κB-inducing kinase–dependent STAT3 signaling in epithelial cells; CD160 expressed by innate-like intraepithelial lymphocytes is the ligand that engages epithelial HVEM for this protective signaling.\",\n      \"method\": \"Hvem-/- mouse infection model, STAT3 phosphorylation assay, CD160 identification as HVEM ligand, gene expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse with mechanistic signaling pathway (NIK–STAT3) and ligand identification (CD160), two infection models\",\n      \"pmids\": [\"22801499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of HVEM (TNFRSF14) causes cell-autonomous B cell proliferation and GC lymphoma development in vivo; HVEM-deficient lymphoma B cells disrupt inhibitory HVEM–BTLA cell–cell contacts, leading to exacerbated lymphoid stroma activation and increased TFH cell recruitment; administration of solHVEM(P37-V202) binds BTLA and restores tumor suppression in vivo.\",\n      \"method\": \"HVEM-KO in vivo lymphoma model, B cell proliferation assay, tumor microenvironment analysis, solHVEM ectodomain treatment, BTLA binding assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO lymphoma model with mechanistic rescue by solHVEM protein, multiple readouts\",\n      \"pmids\": [\"27693350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HVEM on B cells restrains T helper signals delivered to B cells in germinal centers through a cell-extrinsic mechanism: BTLA on T cells signals via the phosphatase SHP1 to reduce TCR signaling and preformed CD40L mobilization to the immunological synapse, diminishing help to HVEM-expressing B cells; T cell BTLA deficiency combined with B cell Bcl-2 overexpression leads to GC B cell outgrowth.\",\n      \"method\": \"Genetic deletion of HVEM on B cells, BTLA KO T cells, imaging of immunological synapse (CD40L mobilization), mixed bone marrow chimeras, Bcl-2 transgenic mice\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic models isolating cell-intrinsic vs extrinsic functions, immunological synapse imaging, SHP1-mediated TCR signaling readout\",\n      \"pmids\": [\"31204070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the CD160–HVEM complex at 2.x Å reveals CD160 adopts a unique Ig fold variant and engages HVEM in a 1:1 complex at a binding interface similar to the BTLA–HVEM interface (CRD1 region), establishing the structural basis for CD160–HVEM bidirectional signaling.\",\n      \"method\": \"X-ray crystallography, light scattering (stoichiometry determination)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — atomic-resolution crystal structure with solution stoichiometry, single lab\",\n      \"pmids\": [\"31230945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures reveal that LIGHT and BTLA/CD160 bind to distinct surfaces on HVEM; a human HVEM–LIGHT–CD160 ternary complex structure demonstrates simultaneous binding of both partners. Structure-guided HVEM knock-in mutants selectively recognizing either TNF or Ig ligands in mice show that LIGHT-HVEM signaling is selectively required for bacterial clearance in the intestine, while Ig ligand (BTLA/CD160)–HVEM signaling is selectively required for amelioration of liver inflammation.\",\n      \"method\": \"X-ray crystallography (ternary complex), structure-based mutagenesis, knock-in mouse models, bacterial infection model, liver inflammation model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ternary crystal structure plus knock-in mouse genetic dissection with two orthogonal in vivo models\",\n      \"pmids\": [\"34709351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HVEM signaling in LIGHT-mediated ILC3 activation is required for host defense against Yersinia enterocolitica; LIGHT is the ligand inducing HVEM signals in ILC3 that stimulate protective IFN-γ secretion; adoptive transfer of wild-type but not IFN-γ-deficient ILC3 restores protection in ILC-deficient mice.\",\n      \"method\": \"HVEM-conditional KO (ILC3-specific), adoptive transfer, IFN-γ production assay, bacterial infection model\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with mechanistic (IFN-γ) and adoptive transfer rescue, two genetic approaches\",\n      \"pmids\": [\"30092201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HVEM expressed in keratinocytes mediates LIGHT-driven keratinocyte hyperplasia and periostin expression; keratinocyte-specific HVEM deletion or antibody blocking of LIGHT-HVEM reduces epidermal thickening, collagen deposition, and periostin in a house dust mite model of atopic dermatitis; LIGHT directly induces keratinocyte proliferation and periostin through HVEM in human epidermal keratinocytes.\",\n      \"method\": \"Keratinocyte-conditional HVEM KO mice, antibody blockade of LIGHT-HVEM, atopic dermatitis model, human keratinocyte culture with LIGHT stimulation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus antibody blockade with mechanistic readouts in both mouse and human cells\",\n      \"pmids\": [\"29339444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNFRSF14 (HVEM) expression on mast cells mediates TNFSF14 (LIGHT)-enhanced IgE-mediated mast cell signaling and mediator production; reconstitution of MC-deficient mice with TNFRSF14-expressing (but not TNFRSF14-deficient) mast cells restores multiple asthma pathology features including airway hyperreactivity, inflammation, and remodeling.\",\n      \"method\": \"Tnfrsf14-KO mice, mast-cell-deficient mouse reconstitution with TNFRSF14+/+ vs TNFRSF14-/- MCs, antibody neutralization, IgE signaling assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two types of MC-deficient mouse reconstitution isolating HVEM function on MCs, with functional IgE signaling readout\",\n      \"pmids\": [\"27982078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HVEM-BTLA pathway controls homeostasis of CD8α- dendritic cell subsets in the spleen; HVEM- or BTLA-deficient DCs show a specific growth advantage in repopulating the spleen in competitive bone marrow chimeras; DC expression of both HVEM and BTLA is required, and LTβR drives DC expansion that is counter-regulated by the HVEM-BTLA inhibitory checkpoint.\",\n      \"method\": \"HVEM-KO and BTLA-KO mice, competitive bone marrow chimera, flow cytometry of DC subsets, LTβR agonist treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — competitive chimera establishes cell-intrinsic function, multiple KO strains, agonist treatment confirms pathway epistasis\",\n      \"pmids\": [\"18097025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTLA expressed on DEC205+CD8+CD11c+ DCs promotes extrathymic Treg induction; HVEM engagement on T cells upregulates CD5, which in turn enables Foxp3 expression by resisting effector-cytokine-mediated suppression of Foxp3; T cells activated in the absence of BTLA-HVEM signaling remain CD5lo and fail to sustain Foxp3.\",\n      \"method\": \"BTLA-KO DC transfer, HVEM-KO T cells, CD5 expression analysis, Foxp3 reporter, cytokine stimulation assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO of both BTLA and HVEM with mechanistic intermediate (CD5 upregulation), multiple cell types tested\",\n      \"pmids\": [\"27793593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LIGHT-HVEM interaction enhances bactericidal activity against Listeria monocytogenes and Staphylococcus aureus in monocytes and neutrophils by increasing phagocytosis, IL-8, TNF-α, nitric oxide, and ROS; anti-HVEM monoclonal antibody blocks all these effects, and ROS/NO inhibition abrogates LIGHT-HVEM-driven bactericidal activity.\",\n      \"method\": \"Anti-HVEM antibody blockade, ROS/NO inhibitors, cytokine ELISA, bactericidal assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-blocking antibody with mechanistic downstream inhibitor studies, single lab\",\n      \"pmids\": [\"16275888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LIGHT (sLIGHT) enhances adipose tissue inflammatory responses (macrophage chemotaxis, cytokine release) through HVEM; neutralizing anti-HVEM antibody or HVEM knockout abolishes sLIGHT-induced inflammatory responses in macrophages, adipocytes, and SVF cells.\",\n      \"method\": \"Anti-HVEM neutralizing antibody, HVEM-KO cells/mice, chemotaxis assay, cytokine ELISA\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-blocking antibody plus genetic KO confirmation, single lab\",\n      \"pmids\": [\"21236258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HVEM promotes CD4+ T cell survival during Strongyloides ratti infection through BTLA engagement; HVEM or BTLA deficiency reduces parasite burden via accelerated mast cell degranulation and increased IL-9 production, placing HVEM upstream of BTLA-mediated suppression of the anti-helminth response.\",\n      \"method\": \"HVEM-KO and BTLA-KO mice, parasite infection model, mast cell degranulation assay, IL-9 measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — parallel genetic KO of both receptor and ligand, functional immune readouts, single lab\",\n      \"pmids\": [\"25595777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BTLA expressed on CD8α+ dendritic cells acts as a trans-activating ligand that delivers positive co-signals through HVEM on T cells to promote CD8 T cell memory formation after vaccinia virus infection; mixed adoptive transfer experiments established the trans (DC-to-T cell) direction of this signaling.\",\n      \"method\": \"HVEM-KO and BTLA-KO mice, vaccinia virus infection, mixed adoptive transfer, memory CD8 T cell quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mixed adoptive transfer establishing cell-type directionality, parallel KO strains, single lab\",\n      \"pmids\": [\"24205056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BTLA expressed on donor T cells serves a dual role in GVHD: (1) as a receptor transmitting inhibitory signals that suppress anti-host T cell responses; and (2) as a ligand that delivers HVEM pro-survival signals to donor T cells, demonstrated using a BTLA mutant lacking the intracellular signaling domain that rescues impaired T cell survival without transmitting inhibitory signals.\",\n      \"method\": \"Agonistic anti-BTLA antibody, BTLA intracellular domain deletion mutant, GVHD mouse model, donor T cell survival assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BTLA signaling-domain mutant dissects receptor vs ligand functions, single lab\",\n      \"pmids\": [\"21220749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MIF (Macrophage Migration Inhibitory Factor) directly binds HVEM and activates NF-κB signaling to promote Th17 cell differentiation; anti-HVEM antibody blockade abolishes MIF-induced Th17 differentiation, establishing HVEM as the receptor mediating MIF's effect.\",\n      \"method\": \"Direct binding assay (MIF–HVEM), anti-HVEM antibody blockade, NF-κB phosphorylation assay, Th17 differentiation assay\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct binding plus functional blockade, single lab, limited methodological detail in abstract\",\n      \"pmids\": [\"37331297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In cis, BTLA co-expression with HVEM results in dominant BTLA-mediated inhibition rather than HVEM co-stimulation; LIGHT and CD160 (but not BTLA) co-expression with HVEM induces constitutive HVEM signaling; HVEM antibodies can simultaneously act as checkpoint inhibitors and co-stimulation agonists on primary human T cells.\",\n      \"method\": \"T cell reporter system, primary human T cell stimulation, HVEM ligand co-expression constructs, NF-κB and NFAT reporter readouts\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter systems plus primary T cell validation, single lab, two orthogonal cell systems\",\n      \"pmids\": [\"36081508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTLA on effector CAR T cells inhibits antitumor function by recruiting tyrosine phosphatases SHP-1 and SHP-2 upon trans engagement with HVEM on regulatory T cells in the tumor microenvironment; BTLA knockout in CAR T cells improves tumor control and persistence in lymphoma and solid tumor models.\",\n      \"method\": \"CRISPR BTLA knockout in CAR T cells, SHP-1/SHP-2 recruitment assay, in vivo tumor models (lymphoma, solid tumors), clinical correlation with CAR T response\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with mechanistic phosphatase recruitment, in vivo validation in multiple tumor models, clinical correlation\",\n      \"pmids\": [\"38831106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HVEM signaling is required for generating ADCC-mediating IgG2 antibodies after HSV vaccination; Hvem-/- mice produce fewer HSV-specific IgG2 antibodies with reduced ADCC titers and impaired FcγR activation; addition of gD protein or anti-HVEM antibodies to in vitro FcγR activation assays inhibits the response, showing gD–HVEM engagement by HSV blocks host ADCC responses.\",\n      \"method\": \"Hvem-/- mouse vaccination, passive serum transfer, in vitro FcγR activation assay, antibody isotyping\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse combined with in vitro mechanistic FcγR assay and passive transfer, multiple orthogonal methods\",\n      \"pmids\": [\"32817296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Epithelial HVEM promotes survival of small intestine intraepithelial T cells (IETs) at steady state by inducing epithelial synthesis of basement membrane protein collagen IV, which engages β1 integrins on IETs; intravital microscopy shows HVEM-deficient epithelium reduces IET patrolling movement; β1 integrin–collagen IV interactions are required for IET maintenance and protective responses to Salmonella.\",\n      \"method\": \"HVEM conditional KO in epithelium, RNA-seq of organoids, β1 integrin-KO T cells, collagen IV measurement, intravital microscopy, Salmonella infection model\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epithelial-conditional KO with mechanistic intermediate (collagen IV–β1 integrin axis), intravital imaging, in vivo infection model, multiple orthogonal approaches\",\n      \"pmids\": [\"35905286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HVEM expression is upregulated in neurons during HSV-1 latency by the viral latency-associated transcript (LAT); LAT upregulates HVEM expression in vivo and in vitro in the absence of other viral factors; HSV-1 latency/reactivation is significantly reduced in Hvem-/- mice, indicating HVEM promotes latency establishment and reactivation.\",\n      \"method\": \"Hvem-/- mouse latency model, LAT expression constructs, in vivo and in vitro HVEM expression measurement, viral latency quantification\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mouse plus LAT expression manipulation, single lab, two orthogonal approaches\",\n      \"pmids\": [\"24307582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LIGHT stimulation through HVEM (but not LTβR) induces upregulation of apoptotic genes and CLL cell death, activation of caspases, loss of mitochondrial membrane potential, upregulation of Bax, and TRAIL involvement; HVEM stimulation also induces endogenous TNF-α production which enhances HVEM-mediated cell death. Other HVEM ligands (gD, BTLA) are largely ineffective in this killing pathway.\",\n      \"method\": \"Anti-HVEM mAb stimulation, LIGHT treatment, caspase activation assay, mitochondrial membrane potential measurement, Bax immunoblot, TNF-α ELISA, receptor-specific blocking\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic apoptosis pathway readouts with receptor-specific ligands and blocking, single lab\",\n      \"pmids\": [\"19701890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFRSF14 deficiency in ovariectomized mice attenuates adipose tissue inflammation by reducing CD11c+ macrophage recruitment and polarization to M1; LIGHT engagement of TNFRSF14 (HVEM) enhances CD11c expression via ROS generation, identifying HVEM as a redox modulator in adipose tissue inflammatory signaling.\",\n      \"method\": \"Tnfrsf14-KO mouse ovariectomy model, flow cytometry of CD11c+ cells, ROS measurement, bone marrow-derived macrophage polarization assay\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with mechanistic ROS pathway readout, single lab\",\n      \"pmids\": [\"24287621\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HVEM (TNFRSF14) is a TNF receptor superfamily member that functions as a bidirectional molecular switch: it acts as a signaling receptor for TNF-family ligands LIGHT and LTα (activating NF-κB via TRAF2/TRAF5 and NIK–STAT3 pathways to drive inflammatory and survival responses) and simultaneously as a ligand for Ig-superfamily members BTLA and CD160, which in trans engagement activate HVEM-dependent NF-κB while in cis the HVEM–BTLA heterodimer on naive T cells is inhibitory; structurally, BTLA and CD160 bind CRD1 of HVEM (the same surface used by HSV gD) while LIGHT binds a distinct surface, allowing ternary complex formation; downstream, HVEM promotes memory T cell survival via Akt, drives epithelial STAT3 activation and collagen IV synthesis to maintain intraepithelial T cells, stimulates ILC3-derived IFN-γ for mucosal defense, and restrains germinal center B cell expansion by limiting TFH help through the BTLA–SHP1 axis, while its frequent somatic mutation or loss in germinal center lymphomas disrupts HVEM–BTLA tumor-suppressive interactions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF14 (HVEM) is a TNF receptor superfamily member that operates as a bidirectional molecular switch coordinating immune signaling, mucosal defense, and tissue homeostasis [#14, #15, #19]. As a signaling receptor, HVEM engages the TNF-family ligand LIGHT (TNFSF14) to activate NF-\\u03baB through a C-terminal intracellular domain that recruits TRAF2 and TRAF5, driving T cell proliferation, survival, and inflammatory responses [#1, #3]. HVEM also functions in reverse as a ligand for the Ig-superfamily receptors BTLA and CD160: in trans these engagements activate HVEM-dependent NF-\\u03baB, whereas in cis the BTLA\\u2013HVEM heterodimer on naive T cells dominantly inhibits HVEM oligomerization and signaling [#13, #31]. Structurally, BTLA and CD160 bind the N-terminal CRD1 of HVEM\\u2014the same surface used by HSV glycoprotein D\\u2014while LIGHT occupies a distinct surface, permitting assembly of a LIGHT\\u2013HVEM\\u2013CD160 ternary complex and genetically separable TNF-ligand versus Ig-ligand functions [#10, #18, #19]. Through these inputs HVEM supports memory T cell persistence via Akt [#14], drives epithelial NIK\\u2013STAT3 signaling and collagen IV synthesis to sustain intraepithelial T cells and antibacterial defense [#15, #34], stimulates ILC3-derived IFN-\\u03b3 [#20], and restrains germinal center B cell expansion through the BTLA\\u2013SHP1 axis [#17]. The inhibitory BTLA arm engages SHP-1/SHP-2 phosphatases, and its loss in HVEM-deficient B cells produces cell-autonomous germinal center lymphoma that is suppressed by soluble HVEM ectodomain binding BTLA [#16, #32]. HVEM is additionally exploited by HSV: gD binding via CRD1 mediates viral entry and cell-cell fusion and blocks host ADCC responses [#0, #4, #33].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing HVEM's first identified function answered how HSV-1 enters cells, defining HVEM as a direct viral entry receptor.\",\n      \"evidence\": \"Biosensor binding and gel filtration with purified gD and HVEM plus CHO cell infection assays\",\n      \"pmids\": [\"9223502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the HVEM residues contacting gD\", \"Cellular signaling consequences of gD binding not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying TRAF2/TRAF5 recruitment and NF-\\u03baB activation answered how the HVEM cytoplasmic tail transduces signals.\",\n      \"evidence\": \"Co-immunoprecipitation and NF-\\u03baB reporter assays with HVEM overexpression\",\n      \"pmids\": [\"9153189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Distinct roles of TRAF2 vs TRAF5 only inferred from synergy\", \"No physiological ligand context in this study\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identifying LIGHT as a physiological HVEM ligand answered what TNF-family input drives HVEM signaling versus apoptosis.\",\n      \"evidence\": \"HVEM-Fc fusion competition, affinity measurement, NF-\\u03baB reporter, T cell proliferation and tumor apoptosis assays\",\n      \"pmids\": [\"9739048\", \"9765287\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apoptotic versus proliferative outcome dependence on receptor co-expression (LT\\u03b2R) not fully resolved\", \"Single-lab affinity measurements\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Crystal structures and truncation mapping answered where gD binds HVEM, localizing the interface to CRD1/CRD2.\",\n      \"evidence\": \"X-ray crystallography of gD\\u2013HveA complex and biosensor/ELISA with truncated HveA and blocking antibodies\",\n      \"pmids\": [\"11511370\", \"11119586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Energetic contribution of individual residues not yet defined\", \"Relationship to other ligand sites not addressed structurally\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Competition mapping answered whether HVEM ligands share or use distinct surfaces, revealing gD, LIGHT, and LT\\u03b1 occupy separable sites with conformational coupling.\",\n      \"evidence\": \"Peptide and soluble receptor competition binding assays with monoclonal antibodies\",\n      \"pmids\": [\"11164894\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Atomic basis of conformational coupling not defined\", \"Ig-superfamily ligands not yet included\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Structure-guided mutagenesis of both partners pinpointed the gD\\u2013HVEM binding hot spot (HveA-Y23, intermolecular \\u03b2-sheet, CRD1 disulfide), distinguishing binding from entry determinants.\",\n      \"evidence\": \"Alanine-scanning and site-directed mutagenesis with biosensor binding and virus entry/fusion assays\",\n      \"pmids\": [\"12368332\", \"12829851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how these residues influence cellular signaling\", \"Generalization to immune ligands not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The BTLA\\u2013HVEM crystal structure answered how an Ig-superfamily receptor engages HVEM, showing CRD1 binding overlapping the gD site.\",\n      \"evidence\": \"X-ray crystallography, light scattering stoichiometry, alanine-scanning mutagenesis of HVEM\",\n      \"pmids\": [\"16169851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of overlap with gD site not tested here\", \"Cis versus trans engagement not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Functional studies answered whether gD\\u2013HVEM engagement itself signals, showing it activates NF-\\u03baB and confers anti-apoptotic protection.\",\n      \"evidence\": \"NF-\\u03baB reporter and apoptosis assays with HVEM-deficient/transfected cells, blocking antibodies, and a gD binding mutant\",\n      \"pmids\": [\"18671825\", \"18723002\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors of anti-apoptotic signaling not fully mapped\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of the cis BTLA\\u2013HVEM heterodimer answered how naive T cells set their signaling baseline, defining a dominant inhibitory configuration.\",\n      \"evidence\": \"Reciprocal Co-IP, surface binding, NF-\\u03baB reporter, and BTLA-KO mice with competitive inhibition assays\",\n      \"pmids\": [\"19915044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise mechanism by which cis BTLA blocks HVEM oligomerization not structurally resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic models answered how HVEM contributes to adaptive immunity, linking LIGHT\\u2013HVEM signaling to memory T cell survival via Akt and to dendritic cell homeostasis via the BTLA checkpoint.\",\n      \"evidence\": \"HVEM-KO and LIGHT-KO mice with antigen recall, Akt phosphorylation and constitutively active Akt rescue, and competitive bone marrow chimeras\",\n      \"pmids\": [\"21402741\", \"18097025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between HVEM and Akt activation not defined\", \"Cell-cell directionality (T-T vs DC) requires distinct models\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Epithelial studies answered how HVEM contributes to mucosal defense, defining a CD160\\u2013HVEM\\u2013NIK\\u2013STAT3 axis protecting against bacterial infection.\",\n      \"evidence\": \"Hvem-/- mouse infection models with STAT3 phosphorylation and CD160 ligand identification\",\n      \"pmids\": [\"22801499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CD160 vs LIGHT in different tissues not yet dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Tumor and Treg studies answered how loss of HVEM\\u2013BTLA interactions promotes malignancy and how the pathway shapes tolerance, establishing HVEM as a B cell tumor suppressor and a CD5/Foxp3-promoting signal.\",\n      \"evidence\": \"HVEM-KO in vivo lymphoma model with solHVEM ectodomain rescue, and BTLA/HVEM-KO models tracking CD5 and Foxp3\",\n      \"pmids\": [\"27693350\", \"27793593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether solHVEM therapy translates beyond the mouse model not addressed\", \"Signaling linking HVEM engagement to CD5 upregulation not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mechanistic and structural studies answered how the inhibitory arm restrains germinal centers and how CD160 engages HVEM, defining a BTLA\\u2013SHP1 cell-extrinsic brake and a CRD1-based CD160 interface.\",\n      \"evidence\": \"Conditional HVEM/BTLA deletion with immunological synapse imaging and SHP1 readout, plus X-ray crystallography of the CD160\\u2013HVEM complex\",\n      \"pmids\": [\"31204070\", \"31230945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative integration of cis and trans signaling in vivo not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The ternary complex structure plus ligand-selective knock-in mice answered whether TNF and Ig ligand arms are genetically separable, showing LIGHT-HVEM and BTLA/CD160-HVEM control distinct tissue functions.\",\n      \"evidence\": \"X-ray crystallography of LIGHT\\u2013HVEM\\u2013CD160 ternary complex with structure-based knock-in mice and infection/inflammation models\",\n      \"pmids\": [\"34709351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How simultaneous ligand binding modulates signaling output quantitatively not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mechanistic dissection in CAR T cells answered how trans BTLA\\u2013HVEM engagement constrains effector function, identifying SHP-1/SHP-2 recruitment as the inhibitory output and a therapeutic target.\",\n      \"evidence\": \"CRISPR BTLA knockout in CAR T cells with phosphatase recruitment assays and in vivo tumor models\",\n      \"pmids\": [\"38831106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HVEM-side signaling contributes to this axis in tumors not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the balance between cis-inhibitory and trans-activating HVEM configurations is dynamically regulated across cell types and disease states, and how this could be therapeutically tuned, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the cis BTLA\\u2013HVEM heterodimer\", \"Mechanism switching cells between cis and trans engagement undefined\", \"Stoichiometry of signaling-competent HVEM clusters in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [13, 16, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 3, 15, 19]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 13, 15, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 15, 17, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 16, 35]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 36]}\n    ],\n    \"complexes\": [\n      \"HVEM\\u2013BTLA cis-heterodimer\",\n      \"LIGHT\\u2013HVEM\\u2013CD160 ternary complex\"\n    ],\n    \"partners\": [\n      \"LIGHT\",\n      \"BTLA\",\n      \"CD160\",\n      \"TRAF2\",\n      \"TRAF5\",\n      \"LTA\",\n      \"MIF\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}